|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accrued expenses | |||||||||||
| Loan from related party | |||||||||||
| Total current liabilities | |||||||||||
| TOTAL LIABILITIES | |||||||||||
| Preferred stock ($0.001 par value, 20,000,000 shares authorized, 5,000 issued and outstanding as of March 31, 2023 and December 31, 2022) | |||||||||||
| Common stock ($0.001 par value, 5,000,000,000 shares authorized, 729,483,160 issued and outstanding as of March 31, 2023 and December 31, 2022) | |||||||||||
| Additional paid in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Total Stockholders' deficit | |||||||||||
| TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT | |||||||||||
Loading...
